The drug and vaccine company Pfizer has signed off on a proposed $44 million class action settlement involving its Chantix medication.
The resolution addresses claims that Chantix, a prescription aid for quitting smoking, reached consumers without proper disclosure of contamination by a nitrosamine compound widely viewed as a probable human carcinogen.
The settlement covers individuals and third-party payers who made retail purchases of the drug across the United States and its territories from September 29th, 2015, through September 17th, 2021.
Eligible claimants must present documentation, such as pharmacy receipts or credit card statements, to request payments from the fund.
“After a determination of the total fund to be allocated to Consumers, each Consumer class member who submits an eligible claim will receive a pro-rata share of the funds based on dollars paid as documented in claim forms and supporting documents submitted, and each consumer’s claim will not exceed the total amount paid for Chantix.”
Class members must submit a claim form here on or before September 14th. The deadline to opt out or object is also September 14th.
Pfizer denies any wrongdoing or liability in the matter but has settled to avoid the uncertainties and expenses associated with ongoing litigation.
The final approval hearing is slated for October 13th of this year.
Follow us on X, Facebook and Telegram
Don’t Miss a Beat – Subscribe to get email alerts delivered directly to your inbox
 
Disclaimer: Opinions expressed at The Daily Hodl are not investment advice. Investors should do their due diligence before making any high-risk investments in Bitcoin, cryptocurrency or digital assets. Please be advised that your transfers and trades are at your own risk, and any losses you may incur are your responsibility. The Daily Hodl does not recommend the buying or selling of any assets including cryptocurrencies, nor is The Daily Hodl an investment advisor. Please note that The Daily Hodl participates in affiliate marketing.
Generated Image: Midjourney